利妥昔-话题@MedSci

#利妥昔#

179篇内容 | 3537人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1660411, encodeId=a61b1660411d7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Am J Hematol：利妥昔单抗治疗非霍奇金淋巴瘤对中枢神经系统复发是否有效？, objectType=article, longId=106878, objectId=53341068e82b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53341068e82b, replyNumber=0, likeNumber=86, createdTime=2017-11-22, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53341068e82b, moduleTitle=Am J Hematol：利妥昔单抗治疗非霍奇金淋巴瘤对中枢神经系统复发是否有效？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53341068e82b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660403, encodeId=b1f11660403b3, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JASN：利妥昔单抗与类固醇加环磷酰胺治疗特发性膜性肾病的安全性比较！, objectType=article, longId=98460, objectId=7a469846078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a469846078, replyNumber=0, likeNumber=66, createdTime=2017-11-03, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a469846078, moduleTitle=JASN：利妥昔单抗与类固醇加环磷酰胺治疗特发性膜性肾病的安全性比较！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a469846078)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660402, encodeId=0713166040216, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Diabetes Care：利妥昔单抗治疗胰岛素自身免疫综合症, objectType=article, longId=98155, objectId=1e259815580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e259815580, replyNumber=0, likeNumber=0, createdTime=2017-10-17, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e259815580, moduleTitle=Diabetes Care：利妥昔单抗治疗胰岛素自身免疫综合症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e259815580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660400, encodeId=f2aa16604007e, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：治疗非霍奇金淋巴瘤，利妥昔单抗与IL21融合，一加一远大于二, objectType=article, longId=97102, objectId=7a3f9e1025a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a3f9e1025a, replyNumber=0, likeNumber=53, createdTime=2018-01-07, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a3f9e1025a, moduleTitle=Blood：治疗非霍奇金淋巴瘤，利妥昔单抗与IL21融合，一加一远大于二, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a3f9e1025a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660396, encodeId=2fc816603964c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=2016CCO实践指南：利妥昔单抗治疗淋巴瘤和慢性淋巴细胞白血病发布, objectType=article, longId=80524, objectId=8e848052465, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e848052465, replyNumber=0, likeNumber=36, createdTime=2017-07-28, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e848052465, moduleTitle=2016CCO实践指南：利妥昔单抗治疗淋巴瘤和慢性淋巴细胞白血病发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e848052465)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660394, encodeId=efd316603945c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：利妥昔单抗可延长B细胞急性淋巴细胞白血病患者生存期, objectType=article, longId=77709, objectId=5f4ae770963, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f4ae770963, replyNumber=0, likeNumber=57, createdTime=2017-06-25, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f4ae770963, moduleTitle=NEJM：利妥昔单抗可延长B细胞急性淋巴细胞白血病患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f4ae770963)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660392, encodeId=3b2e166039210, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Rheumatol：利妥昔单抗治疗RA后乙肝病毒再活化的风险很低, objectType=article, longId=67771, objectId=e9a86e771f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9a86e771f8, replyNumber=0, likeNumber=87, createdTime=2016-07-31, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9a86e771f8, moduleTitle=J Rheumatol：利妥昔单抗治疗RA后乙肝病毒再活化的风险很低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9a86e771f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660395, encodeId=1b4916603956c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet：类风湿性关节炎生物制剂初始治疗：利妥昔单抗or TNF抑制剂？, objectType=article, longId=78325, objectId=ce07e832592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce07e832592, replyNumber=0, likeNumber=68, createdTime=2017-05-21, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce07e832592, moduleTitle=Lancet：类风湿性关节炎生物制剂初始治疗：利妥昔单抗or TNF抑制剂？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce07e832592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660393, encodeId=78c6166039370, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet：利妥昔单抗治疗类风湿关节炎患者优于TNF抑制剂, objectType=article, longId=68437, objectId=6abe6843e19, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6abe6843e19, replyNumber=0, likeNumber=76, createdTime=2017-04-13, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6abe6843e19, moduleTitle=Lancet：利妥昔单抗治疗类风湿关节炎患者优于TNF抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6abe6843e19)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660389, encodeId=b497166038979, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet：10年研究显示利妥昔单抗治疗寻常型天疱疮可获得长期的疗效, objectType=article, longId=61919, objectId=9fb76191944, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fb76191944, replyNumber=0, likeNumber=90, createdTime=2016-04-06, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fb76191944, moduleTitle=Lancet：10年研究显示利妥昔单抗治疗寻常型天疱疮可获得长期的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fb76191944)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660388, encodeId=6b031660388f5, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：来那度胺+利妥昔单抗联合治疗套细胞淋巴瘤, objectType=article, longId=58384, objectId=e0de5838437, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0de5838437, replyNumber=0, likeNumber=73, createdTime=2016-10-13, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0de5838437, moduleTitle=NEJM：来那度胺+利妥昔单抗联合治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0de5838437)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660390, encodeId=d16116603908c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：利妥昔单抗联合免疫球蛋白治疗寻常天疱疮疗效显著, objectType=article, longId=62090, objectId=ff9a62090ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff9a62090ce, replyNumber=0, likeNumber=69, createdTime=2016-12-06, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff9a62090ce, moduleTitle=NEJM：利妥昔单抗联合免疫球蛋白治疗寻常天疱疮疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff9a62090ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660391, encodeId=0f39166039164, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet：利妥昔单抗加化疗治疗伯基特淋巴瘤成人患者效果较好, objectType=article, longId=66397, objectId=a96d6639e1d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a96d6639e1d, replyNumber=0, likeNumber=83, createdTime=2016-10-07, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a96d6639e1d, moduleTitle=Lancet：利妥昔单抗加化疗治疗伯基特淋巴瘤成人患者效果较好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a96d6639e1d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660387, encodeId=1cbd166038eb7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Clin Oncol：来那度胺+利妥昔单抗联合治疗滤泡性淋巴瘤效果更加, objectType=article, longId=58165, objectId=68165816523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68165816523, replyNumber=0, likeNumber=63, createdTime=2016-05-28, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68165816523, moduleTitle=J Clin Oncol：来那度胺+利妥昔单抗联合治疗滤泡性淋巴瘤效果更加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68165816523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660386, encodeId=884a166038664, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Lancet：免疫性血小板减少症使用利妥昔单抗可改善治疗应答, objectType=article, longId=47311, objectId=46694e31173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46694e31173, replyNumber=0, likeNumber=80, createdTime=2016-01-10, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46694e31173, moduleTitle=Lancet：免疫性血小板减少症使用利妥昔单抗可改善治疗应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46694e31173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660385, encodeId=3efe166038587, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Nephrol Dial Transplant：利妥昔单抗—纤维丝样肾小球肾炎新选择, objectType=article, longId=44033, objectId=a39144033e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a39144033e7, replyNumber=0, likeNumber=53, createdTime=2015-04-05, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a39144033e7, moduleTitle=Nephrol Dial Transplant：利妥昔单抗—纤维丝样肾小球肾炎新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a39144033e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660380, encodeId=7d96166038050, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Arthritis Rheumatol：利妥昔单抗成功治疗难治性肌炎患者的临床特征, objectType=article, longId=33086, objectId=820233086de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=820233086de, replyNumber=0, likeNumber=59, createdTime=2014-06-17, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=820233086de, moduleTitle=Arthritis Rheumatol：利妥昔单抗成功治疗难治性肌炎患者的临床特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=820233086de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660383, encodeId=f0af1660383f3, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=The Lancet Oncology：来拉度胺和利妥昔单抗联合用药对惰性非霍奇金淋巴瘤具有较好的耐受性, objectType=article, longId=41415, objectId=a59e41415cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a59e41415cb, replyNumber=0, likeNumber=62, createdTime=2015-02-02, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a59e41415cb, moduleTitle=The Lancet Oncology：来拉度胺和利妥昔单抗联合用药对惰性非霍奇金淋巴瘤具有较好的耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a59e41415cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660375, encodeId=ff6216603e5d7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Ibrutinib利妥昔单抗联合治疗CLL可取得高反应率, objectType=article, longId=28447, objectId=80c32844e10, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80c32844e10, replyNumber=0, likeNumber=73, createdTime=2014-09-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80c32844e10, moduleTitle=Ibrutinib利妥昔单抗联合治疗CLL可取得高反应率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80c32844e10)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660384, encodeId=4f391660384f7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：利妥昔单抗与硫唑嘌呤在ANCA相关性血管炎维持治疗中的效疗效对比, objectType=article, longId=42334, objectId=afe84233417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afe84233417, replyNumber=0, likeNumber=65, createdTime=2015-05-31, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afe84233417, moduleTitle=NEJM：利妥昔单抗与硫唑嘌呤在ANCA相关性血管炎维持治疗中的效疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afe84233417)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利妥昔

2020-05-29

heli0118 (审核中...)

前往app查看评论内容

#利妥昔#

Am J Hematol：利妥昔单抗治疗非霍奇金淋巴瘤对中枢神经系统复发是否有效？

2017-11-22

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JASN：利妥昔单抗与类固醇加环磷酰胺治疗特发性膜性肾病的安全性比较！

2017-11-03

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Diabetes Care：利妥昔单抗治疗胰岛素自身免疫综合症

2017-10-17

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：治疗非霍奇金淋巴瘤，利妥昔单抗与IL21融合，一加一远大于二

2018-01-07

智者为医08 (审核中...)

前往app查看评论内容

#利妥昔#

2016CCO实践指南：利妥昔单抗治疗淋巴瘤和慢性淋巴细胞白血病发布

2017-07-28

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：利妥昔单抗可延长B细胞急性淋巴细胞白血病患者生存期

2017-06-25

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Rheumatol：利妥昔单抗治疗RA后乙肝病毒再活化的风险很低

2016-07-31

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet：类风湿性关节炎生物制剂初始治疗：利妥昔单抗or TNF抑制剂？

2017-05-21

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet：利妥昔单抗治疗类风湿关节炎患者优于TNF抑制剂

2017-04-13

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet：10年研究显示利妥昔单抗治疗寻常型天疱疮可获得长期的疗效

2016-04-06

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：来那度胺+利妥昔单抗联合治疗套细胞淋巴瘤

2016-10-13

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：利妥昔单抗联合免疫球蛋白治疗寻常天疱疮疗效显著

2016-12-06

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet：利妥昔单抗加化疗治疗伯基特淋巴瘤成人患者效果较好

2016-10-07

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Clin Oncol：来那度胺+利妥昔单抗联合治疗滤泡性淋巴瘤效果更加

2016-05-28

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Lancet：免疫性血小板减少症使用利妥昔单抗可改善治疗应答

2016-01-10

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Nephrol Dial Transplant：利妥昔单抗—纤维丝样肾小球肾炎新选择

2015-04-05

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Arthritis Rheumatol：利妥昔单抗成功治疗难治性肌炎患者的临床特征

2014-06-17

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

The Lancet Oncology：来拉度胺和利妥昔单抗联合用药对惰性非霍奇金淋巴瘤具有较好的耐受性

2015-02-02

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Ibrutinib利妥昔单抗联合治疗CLL可取得高反应率

2014-09-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：利妥昔单抗与硫唑嘌呤在ANCA相关性血管炎维持治疗中的效疗效对比

2015-05-31

科室
- - 订阅+
  - 更多科室
工具
服务